[{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"REX-8756","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3300000000000001,"dosageForm":"Oral","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Recludix Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The collaboration aims to advance preclinical studies, REX-8756, an oral, selective and reversible small molecule inhibitor of STAT6. It is being evaluated for asthma, COPD etc.

                          Product Name : REX-8756

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 02, 2025

                          Lead Product(s) : REX-8756

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Sanofi

                          Deal Size : $1,325.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the collaboration, Sanofi will have global rights to small molecule STAT6 inhibitors and Recludix will advance STAT6 inhibitors for patients with immunological and inflammatory diseases, from preclinical R&D until the start of Phase 2 clinical tria...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 20, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Sanofi

                          Deal Size : $1,325.0 million

                          Deal Type : Collaboration

                          blank